Bone biologics announces registered direct offering priced at-the-market under nasdaq rules

Burlington, mass.--(business wire)--bone biologics corporation (nasdaq: bblg), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share in a registered direct offering priced at-the-market under nasdaq rules. in a concurrent private placement, the company has also agreed to issue and sell unregistered w.
BBLG Ratings Summary
BBLG Quant Ranking